{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,3,9]],"date-time":"2026-03-09T22:20:43Z","timestamp":1773094843264,"version":"3.50.1"},"reference-count":17,"publisher":"Springer Science and Business Media LLC","issue":"1","license":[{"start":{"date-parts":[[2026,2,5]],"date-time":"2026-02-05T00:00:00Z","timestamp":1770249600000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by-nc-nd\/4.0"},{"start":{"date-parts":[[2026,3,9]],"date-time":"2026-03-09T00:00:00Z","timestamp":1773014400000},"content-version":"vor","delay-in-days":32,"URL":"https:\/\/creativecommons.org\/licenses\/by-nc-nd\/4.0"}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["BMC Urol"],"DOI":"10.1186\/s12894-026-02064-x","type":"journal-article","created":{"date-parts":[[2026,2,5]],"date-time":"2026-02-05T04:13:42Z","timestamp":1770264822000},"update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":0,"title":["Multimodal management of primary mixed neuroendocrine prostate cancer with bone flare phenomenon: a rare case report and therapeutic insights"],"prefix":"10.1186","volume":"26","author":[{"given":"Lijing","family":"Xu","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Jialin","family":"Wang","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"297","published-online":{"date-parts":[[2026,2,5]]},"reference":[{"key":"2064_CR1","doi-asserted-by":"publisher","unstructured":"Netto GJ, Amin MB, Berney DM, Comp\u00e9rat EM, Gill AJ, Hartmann A, Menon S, Raspollini MR, Rubin MA, Srigley JR, Hoon Tan P, Tickoo SK, Tsuzuki T, Turajlic S, Cree I, Moch H. The 2022 World Health Organization Classification of Tumors of the Urinary System and Male Genital Organs-Part B: Prostate and Urinary Tract Tumors. Eur Urol. 2022;82(5):469\u2013482. Epub 2022 Aug 11. PMID: 35965208. https:\/\/doi.org\/10.1016\/j.eururo.2022.07.002","DOI":"10.1016\/j.eururo.2022.07.002"},{"issue":"1","key":"2064_CR2","doi-asserted-by":"publisher","first-page":"102274","DOI":"10.1016\/j.clgc.2024.102274","volume":"23","author":"R Gagnon","year":"2025","unstructured":"Gagnon R, Kish EK, Cook S, Takemura K, Cheng BYC, Bressler K, Heng DYC, Alimohamed N, Ruether D, Lee-Ying RM, Bose P, Kolinsky MP, Vasquez C, Samuel D, Lewis J, Faridi R, Borkar M, Fairey A, Bismar T, Yip S. Real-world clinical outcomes and prognostic factors in neuroendocrine prostate cancer. Clin Genitourin Cancer. 2025;23(1):102274. https:\/\/doi.org\/10.1016\/j.clgc.2024.102274. Epub 2024 Nov 23. PMID: 39689666.","journal-title":"Clin Genitourin Cancer"},{"key":"2064_CR3","doi-asserted-by":"publisher","first-page":"7","DOI":"10.1016\/j.ejca.2019.08.011","volume":"121","author":"V Conteduca","year":"2019","unstructured":"Conteduca V, Oromendia C, Eng KW, Bareja R, Sigouros M, Molina A, Faltas BM, Sboner A, Mosquera JM, Elemento O, Nanus DM, Tagawa ST, Ballman KV, Beltran H. Clinical features of neuroendocrine prostate cancer. Eur J Cancer. 2019;121:7\u201318. Epub 2019 Sep 13. PMID: 31525487; PMCID: PMC6803064.","journal-title":"Eur J Cancer"},{"key":"2064_CR4","doi-asserted-by":"publisher","unstructured":"Lobo A, Cheng L. Reappraisal of Neuroendocrine Tumor Classification of the Prostate Gland: Translating Molecular Insights into Clinical Practice. Endocr Pathol. 2025;36(1):28. https:\/\/doi.org\/10.1007\/s12022-025-09871-2. PMID: 40699451.","DOI":"10.1007\/s12022-025-09871-2"},{"issue":"8","key":"2064_CR5","doi-asserted-by":"publisher","first-page":"743","DOI":"10.1097\/RLU.0000000000004719","volume":"48","author":"J Cai","year":"2023","unstructured":"Cai J, Xu W, Meng T, Pang Y, Chen H. Visualization of intermetastatic heterogeneity in mixed neuroendocrine Carcinoma-Acinar adenocarcinoma of the prostate by 68 Ga-PSMA, 68 Ga-FAPI, and 18 F-FDG PET\/CT. Clin Nucl Med. 2023;48(8):743\u20135. Epub 2023 May 23. PMID: 37220226.","journal-title":"Clin Nucl Med"},{"key":"2064_CR6","doi-asserted-by":"publisher","unstructured":"Garcia de Herreros M, Jim\u00e9nez N, Rodr\u00edguez-Carunchio L, Lillo E, Mar\u00edn-Aguilera M, Ferrer-Mileo L, Aversa C, Garc\u00eda-Esteve S, Padrosa J, Trias I, Fern\u00e1ndez-Ma\u00f1as L, Font A, Chirivella I, Figols M, Climent M\u00c1, Prat A, Reig \u00d2, Mellado B. Prognostic Expression Signature of RB1, PTEN, and TP53 Genes in Patients with Metastatic Hormone-sensitive Prostate Cancer Treated with Androgen Receptor Pathway Inhibitors. Eur Urol Open Sci. 2024;70:86\u201390. https:\/\/doi.org\/10.1016\/j.euros.2024.10.008. Erratum in: Eur Urol Open Sci. 2025;77:31. doi: 10.1016\/j.euros.2025.05.010. PMID: 39502104; PMCID: PMC11536031.","DOI":"10.1016\/j.euros.2024.10.008"},{"issue":"11","key":"2064_CR7","doi-asserted-by":"publisher","first-page":"5309","DOI":"10.3390\/ijms26115309","volume":"26","author":"M Pedrani","year":"2025","unstructured":"Pedrani M, Salfi G, Merler S, Testi I, Agrippina Clerici CM, Pecoraro G, Castelo-Branco L, Turco F, Tortola L, Vogl U, Gillessen S, Theurillat JP, Zilli T, Mestre RP. Integrating Aggressive-Variant prostate Cancer-Associated tumor suppressor gene status with clinical variables to refine prognosis and predict androgen receptor pathway inhibitor response in metastatic Hormone-Sensitive setting. Int J Mol Sci. 2025;26(11):5309. https:\/\/doi.org\/10.3390\/ijms26115309. PMID: 40508118; PMCID: PMC12154572.","journal-title":"Int J Mol Sci"},{"issue":"4","key":"2064_CR8","doi-asserted-by":"publisher","first-page":"483","DOI":"10.1016\/j.clgc.2023.04.008","volume":"21","author":"CJ Eule","year":"2023","unstructured":"Eule CJ, Hu J, Al-Saad S, Collier K, Boland P, Lewis AR, McKay RR, Narayan V, Bosse D, Mortazavi A, Rose TL, Costello BA, Bryce AH, Lam ET. Outcomes of Second-Line therapies in patients with metastatic de Novo and Treatment-Emergent neuroendocrine prostate cancer: A Multi-Institutional study. Clin Genitourin Cancer. 2023;21(4):483\u201390. Epub 2023 Apr 24. PMID: 37193610; PMCID: PMC10536803.","journal-title":"Clin Genitourin Cancer"},{"issue":"3","key":"2064_CR9","doi-asserted-by":"publisher","first-page":"246","DOI":"10.1007\/s00120-024-02511-3","volume":"64","author":"G von Amsberg","year":"2025","unstructured":"von Amsberg G, Dyshlovoy S, Kaune M. Aggressive varianten und transdifferenziertes neuroendokrines prostatakarzinom: von der diagnose Zur therapie [Aggressive variant prostate cancer and transdifferentiated neuroendocrine prostate cancer: from diagnosis to therapy]. Urologie. 2025;64(3):246\u201355. https:\/\/doi.org\/10.1007\/s00120-024-02511-3. German. doi:.","journal-title":"Urologie"},{"issue":"5","key":"2064_CR10","doi-asserted-by":"publisher","first-page":"635","DOI":"10.1001\/jamaoncol.2022.7762","volume":"9","author":"IB Riaz","year":"2023","unstructured":"Riaz IB, Naqvi SAA, He H, Asghar N, Siddiqi R, Liu H, Singh P, Childs DS, Ravi P, Hussain SA, Murad MH, Boorjian SA, Sweeney C, Van Allen EM, Bryce AH. First-line systemic treatment options for metastatic Castration-Sensitive prostate cancer: A living systematic review and network Meta-analysis. JAMA Oncol. 2023;9(5):635\u201345. https:\/\/doi.org\/10.1001\/jamaoncol.2022.7762. PMID: 36862387; PMCID: PMC9982744.","journal-title":"JAMA Oncol"},{"issue":"10336","key":"2064_CR11","doi-asserted-by":"publisher","first-page":"1695","DOI":"10.1016\/S0140-6736(22)00367-1","volume":"399","author":"K Fizazi","year":"2022","unstructured":"Fizazi K, Foulon S, Carles J, Roubaud G, McDermott R, Fl\u00e9chon A, Tombal B, Supiot S, Berthold D, Ronchin P, Kacso G, Gravis G, Calabro F, Berdah JF, Hasbini A, Silva M, Thiery-Vuillemin A, Latorzeff I, Mourey L, Laguerre B, Abadie-Lacourtoisie S, Martin E, El Kouri C, Escande A, Rosello A, Magne N, Schlurmann F, Priou F, Chand-Fouche ME, Freixa SV, Jamaluddin M, Rieger I, Bossi A. PEACE-1 investigators. Abiraterone plus prednisone added to androgen deprivation therapy and docetaxel in de novo metastatic castration-sensitive prostate cancer (PEACE-1): a multicentre, open-label, randomised, phase 3 study with a 2 \u00d7 2 factorial design. Lancet. 2022;399(10336):1695\u2013707. https:\/\/doi.org\/10.1016\/S0140-6736(22)00367-1. Epub 2022 Apr 8. PMID: 35405085.","journal-title":"Lancet"},{"key":"2064_CR12","doi-asserted-by":"publisher","unstructured":"Roy S, Fervaha G, Spratt DE, Sun Y, Kishan AU, Loblaw A, Malone S, Ong M, Saad F, Wallis CJD, Morgan SC. Prostate Radiotherapy in Low-volume Metastatic Hormone-sensitive Prostate Cancer: A Network Meta-analysis. Eur Urol. 2024;86(1):10\u201317. Epub 2024 Apr 3. PMID: 38570246. https:\/\/doi.org\/10.1016\/j.eururo.2024.03.018","DOI":"10.1016\/j.eururo.2024.03.018"},{"key":"2064_CR13","doi-asserted-by":"publisher","unstructured":"Bossi A, Foulon S, Maldonado X, Sargos P, MacDermott R, Kelly P, Fl\u00e9chon A, Tombal B, Supiot S, Berthold D, Ronchin P, Kacso G, Salem N, Calabro F, Berdah JF, Hasbini A, Silva M, Boustani J, Ribault H, Fizazi K. PEACE-1 investigators. Efficacy and safety of prostate radiotherapy in de novo metastatic castration-sensitive prostate cancer (PEACE-1): a multicentre, open-label, randomised, phase 3 study with a 2\u2008\u00d7\u20082 factorial design. Lancet. 2024;404(10467):2065\u20132076. doi: 10.1016\/S0140-6736(24)01865-8. Erratum in: Lancet. 2025;405(10490):1665. https:\/\/doi.org\/10.1016\/S0140-6736(25)00903-1. PMID: 39580202.","DOI":"10.1016\/S0140-6736(25)00903-1"},{"issue":"4","key":"2064_CR14","doi-asserted-by":"publisher","first-page":"362","DOI":"10.1007\/s11912-025-01643-9","volume":"27","author":"X Zhu","year":"2025","unstructured":"Zhu X, Ding CC, Aggarwal RR. Emerging therapeutic targets of neuroendocrine prostate cancer. Curr Oncol Rep. 2025;27(4):362\u201374. https:\/\/doi.org\/10.1007\/s11912-025-01643-9. Epub 2025 Feb 27. PMID: 40011325.","journal-title":"Curr Oncol Rep"},{"issue":"14","key":"2064_CR15","doi-asserted-by":"publisher","first-page":"4854","DOI":"10.1158\/1078-0432.CCR-11-0815","volume":"17","author":"CJ Ryan","year":"2011","unstructured":"Ryan CJ, Shah S, Efstathiou E, Smith MR, Taplin ME, Bubley GJ, et al. Phase II study of abiraterone acetate in chemotherapy-naive metastatic castration-resistant prostate cancer displaying bone flare discordant with serologic response. Clin Cancer Res. 2011;17(14):4854\u201361. https:\/\/doi.org\/10.1158\/1078-0432.CCR-11-0815.","journal-title":"Clin Cancer Res"},{"issue":"6","key":"2064_CR16","doi-asserted-by":"publisher","first-page":"428","DOI":"10.1007\/s12149-024-01914-8","volume":"38","author":"X Zhang","year":"2024","unstructured":"Zhang X, Nakajima K, Mizokami A, Horikoshi H, Nishimoto K, Hashine K, Matsuyama H, Takahashi S, Wakabayashi H, Kinuya S. Flare phenomenon visualized by 99mTc-bone scintigraphy has prognostic value for patients with metastatic castration-resistant prostate cancer. Ann Nucl Med. 2024;38(6):428\u201340.","journal-title":"Ann Nucl Med"},{"issue":"2","key":"2064_CR17","doi-asserted-by":"publisher","first-page":"324","DOI":"10.1038\/s41391-018-0110-5","volume":"22","author":"AJ Weisman","year":"2019","unstructured":"Weisman AJ, Harmon SA, Perk TG, Eickhoff J, Choyke PL, Kurdziel KA, et al. Quantification of bone flare on (18)F-NaF PET\/CT in metastatic castration-resistant prostate cancer. Prostate Cancer Prostatic Dis. 2019;22(2):324\u201330. https:\/\/doi.org\/10.1038\/s41391-018-0110-5.","journal-title":"Prostate Cancer Prostatic Dis"}],"container-title":["BMC Urology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/link.springer.com\/article\/10.1186\/s12894-026-02064-x","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1186\/s12894-026-02064-x.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1186\/s12894-026-02064-x.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,3,9]],"date-time":"2026-03-09T12:15:36Z","timestamp":1773058536000},"score":1,"resource":{"primary":{"URL":"https:\/\/link.springer.com\/10.1186\/s12894-026-02064-x"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,2,5]]},"references-count":17,"journal-issue":{"issue":"1","published-online":{"date-parts":[[2026,12]]}},"alternative-id":["2064"],"URL":"https:\/\/doi.org\/10.1186\/s12894-026-02064-x","relation":{},"ISSN":["1471-2490"],"issn-type":[{"value":"1471-2490","type":"electronic"}],"subject":[],"published":{"date-parts":[[2026,2,5]]},"assertion":[{"value":"24 September 2025","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"27 January 2026","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"5 February 2026","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Declarations"}},{"value":"Not applicable.The reasons why this case report does not require ethical review are as follows:\n                      Anonymity Protection\n                      : The patient information involved in this case report has been fully anonymized, with all details related to personal identity removed to ensure the privacy of the patient is protected. Therefore, this report does not involve direct ethical concerns regarding any specific individual.\n                      Informed Consent\n                      : The relevant information in this case report has been obtained with the informed consent of the patient or their legal representative. After being fully informed of the contents of the case study, the patient voluntarily agreed to the use of their data for academic research and publication, whether in written or electronic form.\n                      Research Nature\n                      : This case report is primarily intended for educational purposes, practical summaries, and knowledge dissemination within the medical field. Its purpose is to share case experience and clinical management without involving any further experimental interventions or trials on the patient.\n                      Ethical Review Exemption\n                      : In accordance with the guidelines from relevant academic institutions and research ethics committees, due to the nature of this case report being a case study, which does not involve experimental research or long-term intervention on the patient, such reports typically do not require ethical review.In conclusion, this case report is not subject to traditional ethical review procedures, and all necessary measures have been taken to ensure the privacy and rights of the patient are protected to the fullest extent.","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"Ethics approval consent to participate"}},{"value":"The author has obtained individual consent to publish their data prior to submitting the paper to the journal.","order":3,"name":"Ethics","group":{"name":"EthicsHeading","label":"Consent for publication"}},{"value":"The authors declare no competing interests.","order":4,"name":"Ethics","group":{"name":"EthicsHeading","label":"Competing interests"}}],"article-number":"61"}}